Audio

Jeffrey A. Cohen, MD, Describes His Comparison of Alemtuzumab and Interferon Beta-1a in Patients With Multiple Sclerosis

Neurology Reviews. 2012 June;20(6)

 

To read the accompanying article, please click here.

Recommended Reading

Vitamin D Levels Correspond to Disability in MS
MDedge Neurology
FDA Warns of 'Liberation Therapy' Dangers for Multiple Sclerosis
MDedge Neurology
Algorithm May Help Cut PML Risk With Natalizumab
MDedge Neurology
Study Finds Many Missed MS Diagnoses in Emergency Department
MDedge Neurology
Balloon Angioplasty Improves Venous Flow in MS Patients
MDedge Neurology
THC Fails to Delay Progression of Multiple Sclerosis
MDedge Neurology
Metronidazole Encephalopathy Can Mimic MS
MDedge Neurology
Alemtuzumab Will Help Clinicians Treat Patients With MS More Effectively—By Mark Gudesblatt, MD
MDedge Neurology
Alemtuzumab May Be Superior to Interferon Beta-1a in Patients With MS—Results From the CARE-MS II Study
MDedge Neurology
Alemtuzumab May Provide Greater Benefit Than Interferon Beta-1a for Treatment-Naïve Patients With MS—Results From the CARE-MS I Study
MDedge Neurology